期刊文献+

五痹胶囊治疗系统性硬皮病的药效学研究

Pharmacodynamic study of Wubi capsule on sclerosis
下载PDF
导出
摘要 目的研究五痹胶囊治疗系统性硬皮病的药理作用。方法用博来霉素皮下注射建立硬皮病小鼠模型,尾静脉注射1∶1000肾上腺素,造成微循环障碍。随机将小鼠分为正常对照组、模型对照组、五痹胶囊低、中、高剂量组及阳性药物对照组,灌胃给予不同剂量的药物,观察各组小鼠皮肤和肺组织病理学改变、皮肤厚度、胶原含量的变化及耳廓微循环动静脉管径、微血管内红细胞(RBC)流速分值并相互比较。结果各治疗组小鼠皮肤硬化程度可得到一定的改善,皮肤厚度变薄,胶原含量减少,与模型组比较差异均有统计学意义(P<0.01),其中尤以五痹胶囊高剂量组更为突出;给药20、40 min后小鼠耳廓微循环动静脉管径、微血管内RBC流速分值均明显较空白对照组增加(P<0.05,P<0.01)。结论五痹胶囊对硬皮病模型小鼠皮肤厚度、胶原纤维增生有明显的改善作用,并随剂量的增大呈剂量-效应关系;可明显增加模型小鼠耳廓微动脉、微静脉管径,加快微血管内RBC流速,改善小鼠耳廓微循环。提示五痹胶囊能有效地防治系统性硬皮病变的发生是通过抑制胶原纤维的增生、解聚降黏、增加血流量及改善微循环等机制实现的。 Objective To study the pharmacological action of Wubi capsule on sclerosis. Methods Mice model with sclerosis was established by subcutaneous injection of Bleomycin and vena caudalis injection of 1 : 1000 adnephrin. Mouse were randomly divided into control group, model group, positive medicine group, low dosage Wubi group, middle dosage Wubi group and high dosage Wubi group. Different dosage of Wubi were lavaged. The changes of skin, lung histopa- thology and thickness of skin, collagen content, caliber of microeirculation of ala auris artery, vein and flow value of RBC were observed. Results Degree of skin harden were improved; thickness of skin was thinningzd and content of collagen were decreased in each treatment groups ( P 〈 0.01 ). Caliber of microcirculation of ala auris artery,vein and flow value of RBC were increased after 20min, 40min of administration ( P 〈 0.05 or P 〈 0.01 ). Conclusion Wubi capsule has an effect of improving thickness of mice skin and collagen fibers hyperplasy.
出处 《河北中医》 2007年第3期262-265,共4页 Hebei Journal of Traditional Chinese Medicine
基金 河北省科技攻关项目(编号:03146493A)
关键词 系统性硬皮病 微循环 博来霉素 疾病模型 动物 Systemic sclerosis Microcirculation Bleomycin Disease Model Animal
  • 相关文献

参考文献6

二级参考文献21

  • 1杨映波 王正国 等.100例我国正常人循环内皮细胞的数量及形态学研究[J].中华医学检验杂志,1993,16(1):36-38.
  • 2Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol,1999,112:456-462.
  • 3Judy VD, Gershwin ME. An inherited fibrotic disease of white Leghorn chickens resembling progressive systemic sclerosis. Am J Pathol, 1985,120 : 478-482.
  • 4Bennett JP, Burns CP. Absence of progress of recurrent bleomycin skin toxicity without postponement or attenuation of therapy. Am J Medicine, 1988,85 : 585-586.
  • 5Yamamoto T, Katayama I, Nishioka K. Fibroblast proliferation by bleomycin stimulated perpheral blood mononuclear cell factors. J Rheumatol, 1999,26 : 609-615.
  • 6Oder WA, Noble NA. Transforming growth factor β in tissue fibrosis. New Engl J Med, 1994,331 : 1286-1292.
  • 7Karukonda SR, Flynn TC, Boh EE, et al. The effects of drugs on wound healing: part 1. Int J Dermatol, 2000,39 : 250-257.
  • 8Higley H, Persichitte S, Chu S, et al. Immunocytochemical localization and serologic detection of transforming growth factor beta-1:association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum, 1994,37:278-288.
  • 9Kissin EY, Lemaire R, Kom JH, et al. Transforming growth factor beta induces fibroblast fibrillin-1 matrix formation. Arthritis Rheum, 2002,46 : 3000-3009.
  • 10Yamamoto T, Takagama S, Katayama I, et al. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. J Clin Immunol, 1999,92 : 6-13.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部